NASDAQ / LIVE COMPANY INTELLIGENCE

Iovance Biotherapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERIOVA
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / IOVA COVERAGE

What’s moving Iovance Biotherapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

The story matters when it changes Iovance Biotherapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
IOVA BREAKING NEWS: Iovance Biotherapeutics, Inc. Stock Plummets 44% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:IOVA)

IOVA BREAKING NEWS: Iovance Biotherapeutics, Inc. Stock Plummets 44% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:IOVA)

Investors are testing whether Iovance Biotherapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

The story matters when it changes Iovance Biotherapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Iovance Biotherapeutics, Inc. to Report First Quarter 2025 Financial Results and Corporate Updates on May 8, 2025

Iovance Biotherapeutics, Inc. to Report First Quarter 2025 Financial Results and Corporate Updates on May 8, 2025

The story matters when it changes Iovance Biotherapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock

Investors are testing whether Iovance Biotherapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest IOVA filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-06 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-24 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-02 · Period 2026-06-30SEC ↗8-KMaterial company eventFiled 2026-06-10 · Period 2026-06-04SEC ↗8-KMaterial company eventFiled 2026-05-07 · Period 2026-05-07SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-28 · Period 2026-06-10SEC ↗SCHEDULE 13G/AOfficial SEC filingFiled 2026-07-28SEC ↗
EARNINGS / QUARTERLY TRACKER

Iovance Biotherapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.